Free and confidential
Request a GLP-1 Injury Case Review
Speak with an attorney about the medication used, the injury involved, and the next steps that may be available.
Important: This website provides legal information and helps prospective clients contact an attorney. Contacting the site does not create an attorney-client relationship. A matter may be evaluated, referred to, or handled with co-counsel, and representation begins only through a written agreement.
Blindness is one of the most severe injuries alleged in connection with GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Saxenda, and Victoza. A growing number of patients report sudden vision loss, often diagnosed as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
Some research has indicated that patients prescribed semaglutide may have a greater chance of a Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) diagnosis. Recently, there is more data showing there is at a minimum an association between GLP-1 prescriptions and NAION. However, there isn’t appropriate clinical research to definitively prove that semaglutide causes NAION. The primary reason for this is because type 2 diabetes is a risk factor associated with NAION and various eye medical issues.
In 2024 there was a study from Mass Eye and Ear set forth in JAMA Ophthalmology. Patients prescribed semaglutide had a four times greater chance of a NAION diagnosis compared to patients prescribed other diabetes drug scripts. Among obese people with a semaglutide script, the risk increased to more than seven times. A new study in the Europe continent suggests an important increase in NAION among patients with semaglutide prescription over a long period of time who also had diabetes. The European Medicines Agency is conducting a risk assessment and suggests the need for label warnings. Currently, there is an MDL in Federal Court where litigants may pursue an Ozempic lawsuit. People may also file a GLP-1 blindness lawsuit in State Court in New Jersey in the Multicounty litigation. Because NAION can cause permanent, irreversible blindness, these claims are treated as a separate, high-severity injury category in GLP-1 litigation and are now handled in their own federal MDL.
What Is NAION?
NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) is a condition caused by reduced blood flow to the optic nerve.
Key characteristics:
- sudden, painless vision loss
- often occurs upon waking
- commonly affects one eye
- damage is frequently permanent
- no proven treatment to restore lost vision
- NAION is considered a medical emergency.
Loss of vision resulting from NAION is an untreatable issue that may cause permanent blindness. Vision loss from NAION is normally sudden, and usually only realized when a patient awakens in the am and realizes vision loss in one eye. Patients with a confirmed NAION diagnosis have blurred or darkened vision which may obstruct their field of view. Victims may also experience decrease of color vision as well as decrease of contrast in vision. 15% of patients suffer with NAION in one eye are also diagnosed with NAION it their other eye. Most people with a NAION diagnosis, will not have improved vision over time. Certain victims will endure their vision getting progressively worse subsequent to initial loss of vision.
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a severe, scary and generally irreversible condition of the eye (sometimes referred to as “eye stroke”). NAION can lead to abrupt, loss of vision in one eye which is painless. NAION constitutes a severe eye condition that leads to sudden, usually painless, loss of vision or blurry vision as a result of low blood flow to the optic nerve. NAION may manifest itself without warning, literally, often within hours. NAION occurs if blood flow to the optic nerve is blocked, reduced or lowered, which may cause blindness. The optic nerve will fail to regenerate. NAION causes optic nerve damage and unexplained loss of vision. Poonja S, Chen JJ. Re-examining the putative association between GLP-1 receptor agonists and nonarthritic anterior ischemic optic neuropathy. Ann Eye Sci 2025;10:5–5. [Google Scholar] NAION is the 2nd biggest cause of vision loss linked to optic nerve damage after glaucoma.
Nonetheless, many people with a GLP-1 script are oblivious to it before their NAION diagnosis. Such vision loss usually happens overnight. NAION could also result in a change in color perception as well as progressive vision loss. NAION is very problematic because NAION cannot be managed or improved with the best medical intervention. The American Academy of Ophthalmology determined that NAION is the most ubiquitous cause of acute optic nerve damage in victims greater than 49 years of age. Even though NAION frequently, occurs, numerous aspects of it, remains unknown or perhaps unproven. NAION’s pathogenesis and worthwhile treatments remain relatively unknown. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmology 2024;142:732–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
Am I eligible to File a Lawsuit for Ozempic Blindness?
A litigant may qualify to file an Ozempic lawsuit if the person meets the Ozempic lawsuit criteria:
- Victim prescribed GLP-1 drug.
- Victim has sudden loss of vision, optic nerve damage, or a confirmed NAION diagnosis.
- Person has medical reports which indicate both a diagnosis and medical treatment.
- Person has not signed a waiver of liability or already reached a written settlement of their possible claim for damages.
- Victims who have have received partial compensation could possibly still qualify for an Ozempic payout and receive compensation.
Vision Loss Reported After GLP-1 Drug Use
Reported symptoms include:
- sudden blindness in one eye
- partial vision loss or dark spots
- blurred or dim vision
- loss of peripheral vision
- permanent visual field defects
Many patients report no prior warning signs.
How GLP-1 Drugs May Contribute to NAION
Medical experts are evaluating several mechanisms:
A. Blood Pressure & Nocturnal Hypotension
GLP-1 drugs may lower blood pressure, especially overnight — a known NAION risk factor.
B. Dehydration & Volume Depletion
Vomiting and reduced fluid intake can decrease optic nerve perfusion.
C. Rapid Metabolic Changes
Rapid weight loss and vascular changes may increase ischemic vulnerability.
Who Is at Higher Risk?
Risk factors include:
- diabetes
- hypertension
- sleep apnea
- cardiovascular disease
- smoking history
- age 40+
- “crowded” optic nerve anatomy
Many GLP-1 users fall into multiple overlapping risk categories.
Why Blindness Claims Are Treated Separately
Vision loss cases differ because:
- blindness is often permanent
- damages are lifelong
- causation analysis is ophthalmologic
- expert testimony differs from GI cases
As a result, NAION cases are not grouped with gastroparesis or GI MDLs.
MDL overview: MDL
Evidence Used in NAION Lawsuits
Strong claims often include:
- ophthalmology or neuro-ophthalmology records
- OCT imaging and fundus photography
- visual field testing
- ER or urgent ophthalmology visits
- documented sudden onset
- GLP-1 prescription history
What are some signs of NAION?
- Abrupt loss of vision: Typically occurs within hours or even days.
- Unilateral loss of vision: Vision loss in one eye.
- Blurriness: Blurry vision.
- Cloudiness: Dim vision, blurry or perhaps even gray.
- Vision loss (Central): Visual field in the center may be affected, causing issues reading or even perhaps viewing details.
- Peripheral vision could still be preserved: Even though central vision may be impaired, peripheral vision could still be good.
- No pain or redness in eye: The opposite of other eye issues, NAION rarely leads to pain or redness.
- Could coincide with other complications: Certain people could have dizziness, headaches, or even nausea side effects.
Who May Qualify for a Blindness Claim Review
You may qualify if:
- you used a GLP-1 drug, AND
- you experienced sudden vision loss, AND
- you were diagnosed with NAION or optic nerve ischemia, AND
- vision did not fully recover
Start here: File a Claim
Medical Research and Regulatory Context
The scientific foundation for the growing wave of Ozempic and Wegovy vision-loss litigation traces back to a July 2024 study published in JAMA Ophthalmology by researchers at Massachusetts Eye and Ear, a Harvard-affiliated teaching hospital. The retrospective cohort study, led by Dr. Jimena Tatiana Hathaway, examined nearly 17,000 patients evaluated at a single neuro-ophthalmology practice and found that semaglutide patients faced a more than fourfold increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) if being treated for type 2 diabetes, and a more than sevenfold increased risk if being treated for obesity, compared to patients on non-GLP-1 alternatives. NAION causes sudden, permanent, and currently untreatable vision loss, and the study’s authors were careful to frame their findings as an association requiring further research, not proof that semaglutide causes the condition. That caveat, however, did little to slow what followed.
In the eighteen months since the Hathaway study’s publication, the medical and regulatory response has been substantial. The European Medicines Agency opened a formal safety review of semaglutide and NAION in January 2025, and by June 2025 the agency had concluded the review by classifying NAION as a very rare side effect of semaglutide and recommending corresponding updates to the drug’s product labeling in Europe. Independently, pharmacovigilance researchers mining the FDA’s Adverse Event Reporting System identified a statistically disproportionate signal of NAION reports associated with semaglutide, including a notable surge in reports originating from Denmark in the final months of 2024, further fueling regulatory attention on both sides of the Atlantic.
Perhaps more significant for litigation purposes than the original single-center study is what came after it: a series of larger, methodologically varied replication attempts. A major 2025 study led by Dr. Cindy Cai and colleagues, also published in JAMA Ophthalmology, used the OHDSI research network to examine the semaglutide-NAION question across 14 separate databases, six administrative claims databases and eight electronic health record systems, representing a dramatically larger and more diverse dataset than the original Harvard cohort. Around the same time, a separate 2025 study by Dr. Alan Hsu and colleagues, again in JAMA Ophthalmology, was described by commentators as the largest study of the association to date. Notably, results across this expanding body of research have not been uniformly consistent, prompting an accompanying JAMA Ophthalmology editorial titled “Conflicting Results — Need for More Transparent and Reproducible Research,” a pointed acknowledgment from the journal itself that the picture remains scientifically unsettled even as it continues to sharpen.
Additional corroborating evidence has since emerged from multiple independent populations. A Danish-Norwegian cohort study published in Diabetes, Obesity and Metabolism in 2025 examined national registry data across two countries. A multinational population-based study published in the journal Ophthalmology similarly evaluated the association across several countries’ health systems. And in one of the most methodologically robust analyses to date, a U.S. Department of Veterans Affairs study published in JAMA Ophthalmology followed more than 102,000 veterans with type 2 diabetes for up to 7.5 years, comparing those started on semaglutide against those started on an SGLT2 inhibitor. That study found NAION developed in roughly 0.29% of semaglutide patients compared to 0.13% of SGLT2 inhibitor patients, a roughly twofold relative increase, notably smaller than the fourfold to sevenfold hazard ratios reported in the original Harvard study, but still a statistically meaningful signal drawn from the longest follow-up period and one of the largest patient populations studied to date. A 2025 systematic review and meta-analysis, also published in JAMA Ophthalmology, has since attempted to pool this expanding body of evidence into a single aggregated risk estimate.
For attorneys evaluating or litigating semaglutide-related vision loss claims, this expanding research record cuts in more than one direction. On one hand, the fact that multiple independent research teams, using different databases, different countries, different comparator drugs, and different methodologies, have now repeatedly identified an elevated NAION signal considerably strengthens a general causation argument beyond what a single-center study could support on its own, and the EMA’s formal regulatory finding adds meaningful weight as an independent, non-litigation-driven determination. On the other hand, the acknowledged inconsistency between studies, the JAMA editorial explicitly flagging conflicting results, the comparatively modest relative risk found in the largest and longest VA analysis, and the persistently low absolute risk to any individual patient are exactly the vulnerabilities defense experts are likely to emphasize in challenging plaintiffs’ general causation showing. As this litigation moves through early bellwether and Daubert-stage proceedings, expect both sides to lean heavily on this now-substantial and still-growing body of post-2024 research to make their respective cases.
Ozempic-Specific Vision-Loss Evidence
Medical experts are examining whether Ozempic may contribute to NAION through:
- blood pressure lowering effects
- dehydration from nausea and vomiting
- rapid metabolic and vascular changes
- interaction with pre-existing diabetic or vascular risk factors
Records Used in Ozempic NAION Claims
Important documentation includes:
- ophthalmology records
- optic nerve imaging
- visual field tests
- emergency visit records
- Ozempic prescription and dosage history
Do You Need an FDA Report to File a Claim?
No. FDA reports are not required.
Legal claims focus on:
- medical diagnosis
- severity and permanence
- timing relative to drug use
- functional impact
Related GLP-1 Lawsuit Resources
- GLP-1 multidistrict litigation overview
- Current GLP-1 drug lawsuits
- Request a confidential claim review
Related Resources
Continue with the main resource, closely related topics, and a useful cross-reference.
- Pillar: GLP-1 Drug Lawsuits (2026)
- Related topic: GLP-1 MDL Explained (2026)
- Related topic: GLP-1 Regulatory Updates, Approvals and Label Changes (2026)
- Also review: Common Side Effects of GLP-1 Drugs